3,000 Feet Beneath the Ocean, Scientists Found Spiders With a Hidden Superpower
Here's what you'll learn when you read this story:
In 2023, scientists from the Occidental College of Los Angeles collected 36 specimens of sea spider living near methane seeps along the Pacific Coast from California to Alaska.
Upon examining the arachnid-like creatures, they discovered that these deep sea species form a symbiotic relationship with methylotrophic bacteria, which provide a food source in the pitch dark aphotic zone.
This new study paints a more complete picture of how the deep sea helps keep methane (a potent greenhouse gas) from escaping into the atmosphere.
When you live in the ocean's aphotic zone, where absolute darkness reigns, you need some creative solutions to some pretty existential questions. Chief among them: what are you going to eat?
For a variety of ocean floor-dwelling species, including mussels, worms, and sponges, that answer lies with chemosynthetic bacteria—organisms that flourish around methane seeps where the gas escapes the Earth's crust. A new study shows that three species of the sea spider genus Sericosura also demonstrate a similar ability, which helps explain why these spindly-legged organisms are found in such abundance near methane seeps. The results of the study were published in the journal Proceedings of the National Academy of Sciences (PNAS).
Despite the name, sea spiders aren't actually spiders (though, that'll likely be of little comfort to an arachnophobe). Although they look remarkably similar, sea spiders have a thinner cephalothorax than their eight-legged land-based lookalikes, and their legs tend to have more joints. Oh, and they also live in the deep ocean—one of biology's true final frontiers of scientific inquiry. This hard-to-reach ecosystem is why many aspects of their lives remain a mystery.
'Our study aimed to examine the ways in which often overlooked animals might take advantage of novel energy sources, such as methane,' Shana Goffredi, the senior author of the study from the Occidental College of Los Angeles, said in a press statement. 'While the deep sea feels far away, all organisms are interconnected, and the processes in one ecosystem affect another.'
In 2023, Goffredi—along with two students, including Bianca Dal Bó—embarked on a two-week research expedition on the R/V Atlantis to study these creatures in their deep-sea habitats. With the help of a piloted submersible named Alvin, they examined and collected sea spider specimens located 1,000 meters (3,280 feet) below the ocean surface from the Del Mar and Palos Verdes seeps in California and the Sanak seep in Alaska. Of the 36 specimens recovered, three of the spiders represented entirely new species.
'I had seen animal samples in preservatives in the lab for so long, so it was beautiful to finally see them moving around in their natural habitat,' Dal Bó said in a press statement. 'It made me feel all the more connected to my project and these fascinating ecosystems.'
While performing experiments on board, Goffredi and Dal Bó incubated the sea spiders in seawater with methanol and a heavy isotope of methane. Because this isotope is rare in nature, the researchers could track its impact on the sea spiders, including if it was ingested. They found that methylotrophic bacteria located on the sea spiders' exoskeletons served as a source of a food.
'Evidence from tissue isotopic analysis, microbiome sequencing, and live-animal incubations followed by 13C-methane isotope probing confirms active incorporation of methane-derived carbon into spider tissues,' the authors wrote. 'This research highlights a previously unknown interaction between an animal lineage and chemically fueled microbes, introducing another symbiotic pathway for direct microbial transfer of methane carbon into animal biomass in the deep sea.'
This transfer of methane carbon into animal biomass is particularly important for scientists to understand, as methane is one of the most potent greenhouse gases. Sea spiders—with the help of other deep ocean-dwelling animals—are doing their part to keep these gases locked away in the ocean, so they don't reach the atmosphere and exacerbate the ongoing climate crisis.
'While the deep sea feels really far away, all organisms are interconnected,' Goffredi told CNN. 'Even though they're small, these animals have a big impact in that environment. We can't ever hope to sustainably (use) the oceans if we don't really understand the oceans.'
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
3,000 Feet Beneath the Ocean, Scientists Found Spiders With a Hidden Superpower
Here's what you'll learn when you read this story: In 2023, scientists from the Occidental College of Los Angeles collected 36 specimens of sea spider living near methane seeps along the Pacific Coast from California to Alaska. Upon examining the arachnid-like creatures, they discovered that these deep sea species form a symbiotic relationship with methylotrophic bacteria, which provide a food source in the pitch dark aphotic zone. This new study paints a more complete picture of how the deep sea helps keep methane (a potent greenhouse gas) from escaping into the atmosphere. When you live in the ocean's aphotic zone, where absolute darkness reigns, you need some creative solutions to some pretty existential questions. Chief among them: what are you going to eat? For a variety of ocean floor-dwelling species, including mussels, worms, and sponges, that answer lies with chemosynthetic bacteria—organisms that flourish around methane seeps where the gas escapes the Earth's crust. A new study shows that three species of the sea spider genus Sericosura also demonstrate a similar ability, which helps explain why these spindly-legged organisms are found in such abundance near methane seeps. The results of the study were published in the journal Proceedings of the National Academy of Sciences (PNAS). Despite the name, sea spiders aren't actually spiders (though, that'll likely be of little comfort to an arachnophobe). Although they look remarkably similar, sea spiders have a thinner cephalothorax than their eight-legged land-based lookalikes, and their legs tend to have more joints. Oh, and they also live in the deep ocean—one of biology's true final frontiers of scientific inquiry. This hard-to-reach ecosystem is why many aspects of their lives remain a mystery. 'Our study aimed to examine the ways in which often overlooked animals might take advantage of novel energy sources, such as methane,' Shana Goffredi, the senior author of the study from the Occidental College of Los Angeles, said in a press statement. 'While the deep sea feels far away, all organisms are interconnected, and the processes in one ecosystem affect another.' In 2023, Goffredi—along with two students, including Bianca Dal Bó—embarked on a two-week research expedition on the R/V Atlantis to study these creatures in their deep-sea habitats. With the help of a piloted submersible named Alvin, they examined and collected sea spider specimens located 1,000 meters (3,280 feet) below the ocean surface from the Del Mar and Palos Verdes seeps in California and the Sanak seep in Alaska. Of the 36 specimens recovered, three of the spiders represented entirely new species. 'I had seen animal samples in preservatives in the lab for so long, so it was beautiful to finally see them moving around in their natural habitat,' Dal Bó said in a press statement. 'It made me feel all the more connected to my project and these fascinating ecosystems.' While performing experiments on board, Goffredi and Dal Bó incubated the sea spiders in seawater with methanol and a heavy isotope of methane. Because this isotope is rare in nature, the researchers could track its impact on the sea spiders, including if it was ingested. They found that methylotrophic bacteria located on the sea spiders' exoskeletons served as a source of a food. 'Evidence from tissue isotopic analysis, microbiome sequencing, and live-animal incubations followed by 13C-methane isotope probing confirms active incorporation of methane-derived carbon into spider tissues,' the authors wrote. 'This research highlights a previously unknown interaction between an animal lineage and chemically fueled microbes, introducing another symbiotic pathway for direct microbial transfer of methane carbon into animal biomass in the deep sea.' This transfer of methane carbon into animal biomass is particularly important for scientists to understand, as methane is one of the most potent greenhouse gases. Sea spiders—with the help of other deep ocean-dwelling animals—are doing their part to keep these gases locked away in the ocean, so they don't reach the atmosphere and exacerbate the ongoing climate crisis. 'While the deep sea feels really far away, all organisms are interconnected,' Goffredi told CNN. 'Even though they're small, these animals have a big impact in that environment. We can't ever hope to sustainably (use) the oceans if we don't really understand the oceans.' You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?


Associated Press
20 hours ago
- Associated Press
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Jun 25, 2025-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4 'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.' BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. 'Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.' PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. 'It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.' DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: . References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol . 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol . 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch . 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio ® U.S. Prescribing Information. Available online . Accessed June 2025 6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR . 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online . Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed June 2025 View source version on CONTACT: For further information: Christian Marcoux, Chief Communications Officer [email protected] +41 76 315 26 50 Richard Harbinson Corporate Communications Director [email protected] +41 76 210 60 62 Céline Buguet Franchises and R&D Communications Director [email protected] +41 76 249 90 87 Emil Ivanov Head of Strategy, Investor Relations, and ESG [email protected] +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director [email protected] +41 21 642 76 43 KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Galderma Copyright Business Wire 2025. PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM


UPI
a day ago
- UPI
Japan's ispace blames 'hard landing' on moon on Laser Range Finder
Japanese company ispace said the recent "hard landing" of its attempted lunar landing was due to a failure of the Laser Range Finder. File Photo by James Atoa/UPI | License Photo June 24 (UPI) -- Japanese company ispace said Tuesday that a "hard landing" during its attempted lunar landing in early June was due to an anomaly in the Laser Range Finder. In the analysis of the "SMBC X HAKUTO-R VENTURE MOON" mission 2 ispace said the hard landing was due to an "anomaly in the laser rangefinder hardware," and the telemetry data also revealed no issues with the lander's software or propulsion system. The LRF unit did not provide altitude measurement until it was less than half a mile off the ground. However, it was initially designed to provide altitude data when the spacecraft was at at least about 2 miles above the surface. Laser light reflected back to the lander, lower power of the laser, reduced performance at higher velocities or effects from the space environment, such as a vacuum or radiation are several factors that could have played a role in the performance of the LRF. "On June 6, despite the united efforts and dedication of the ispace team, our second attempt at a lunar landing was unsuccessful, resulting in deep disappointment," said Founder and CEO of Ispace Takeshi Hakamada. "We deeply regret that we were unable to meet the expectations of our shareholders, payload customers, HAKUTO-R partners, government officials, and all others who supported us." "Ispace will not let this be a setback. We will not stop here, but as determined pioneers of the cislunar economy, we will strive to regain the trust of all stakeholders and embark on the next mission. Chief technology officer at ispace Ryo Ujiie said the company was taking major steps to combat the problem. One is to conduct a better testing plan to see how the laser rangefinder operates under different conditions. The second is to look into getting a different laser rangefinder. These changes will not be in effect for missions 3 and 4, which are scheduled to launch in 2027. "We take it very seriously," Takeshi Hakamada, chief executive of ispace, said of the failed landings of its first two missions. "However, the important part is that we keep trying. There can be some failures, but we keep improving our systems." "Our primary goal today was to convey that ispace, as a challenger, is already moving forward towards its next mission," he said, vowing to regain the trust of its customers and other stakeholders. "We're committed to demonstrating that Ispace will continue to grow undeterred by this setback." "We take it very seriously," Takeshi Hakamada, chief executive of ispace, said of the failed landings of its first two missions. "However, the important part is that we keep trying. There can be some failures, but we keep improving our systems." "Our primary goal today was to convey that ispace, as a challenger, is already moving forward towards its next mission," he said, vowing to regain trust of its customers and other stakeholders. "We're committed to demonstrating that ispace will continue to grow undeterred by this setback."